Persistence Market Research Blog

Archive for the ‘Healthcare’ Category

Anal Cancer Therapeutics Market : Global Industry Analysis and Forecast 2016 – 2024

A cancer can be defined when the normal cells lose their ability to control, their growth or multiplication and thus invade the tissues and spread to the body parts. Anal cancer is often called as squamous cell carcinoma which arises from the cells around or in the anal opening or in rare cases it may cause in the anal canal. This type of cancer is usually associated with human papiloma virus (HPV), where HPV cancers or cervical cancers have a high risk of developing into anal cancer. There are no exact symptoms for anal cancer as such but some might show bleeding from the anal area, lump or swelling near anus or change in the bowel habits etc.  Staging is a way which describes the location of cancer, the stages include tumor, node and metastasis which is further grouped I, II, IIIA, IIIB and IV. The different types of anal cancer include melanoma, adenocarcinoma, basaloid transitional and cloacogenic cancer.

Interested in report: Please follow the below links to meet your requirements; Request for the Report Sample: http://www.persistencemarketresearch.com/samples/10658

The statistics for anal cancer suggest that annually there about 6000 cases of anal cancer diagnosed in the U.S. and the number is increasing slowly. The major factors that drive the market for anal cancer therapeutics are aging population, sexually transmitted disease, multiple sexual partners and smoking. According to the World Health Organization 290 million women are suffering from HPV infection and due to unhealthy sex, the chances get doubled. For treating this anal cancer, early diagnosis is crucial which is only available in the developed countries or high-income countries and are accessible. Whereas in the low-income countries the diagnosis and treatment facilities are either costly or inaccessible. These factors are responsible for holding back the anal cancer therapeutics market and should be well tracked for future advancements.

The anal cancer therapeutics market can be classified on the basis of product type and distribution channel.

According to the product type, the anal cancer therapeutics can be sun-divided into the following:

  • Chemotherapy drugs
    • Fluorouracil
    • Cisplatin
    • Carboplatin

According to the distribution channel, the anal cancer therapeutics can be sun-divided into the following:

  • Hospitals
  • Long-term care centers
  • Pharmacies
  • Diagnostic Laboratories

Altogether 80% of anal cancers are developed after the age of 60 and the ones which occur prior to age 35 are mostly observed in men. Almost half of the anal caners are diagnosed before the cancer turns to be malignant but when the cancer is found through early diagnosis are treatable. The survival rate of anal cancer in male is 60% and 70% in female for 5 years. Most of the anal cancers are treated with combination therapy and some are treated with surgery when early diagnosed. Cancer treatment includes chemotherapy, radiation therapy and surgery which is also dependent on the stage of the tumor.

Worldwide there are 1 or 2 cases per 100000 cases and accounts for about 1.5 % of the cases in the United States. Anal cancer therapeutics market share is more in North America followed by Europe. In U.K the incidence cases did not grow in the past few years and thus the anal cancer accounts for less than 1% of all the deaths. In the developed countries and developing countries several epidemiologic studies have found out that the chances for developing anal cancer can be directly related to sexual practices. Also the number of the sexually transmitted diseases has increased over the past couple of years leading to rise in the number of diseases and infections. The developed countries have proper healthcare facilities and thus treatment for anal cancer is possible.

Request TOC (table of content), Figures and Tables of the Report: http://www.persistencemarketresearch.com/toc/10658

The major market players in the anal cancer therapeutics are GlaxoSmithKline Pharmaceuticals Ltd., Spectrum Pharmaceuticals, Inc., Hospira, Inc., Global BioPharma, Inc., and Advaxis, Inc.

The report covers exhaustive analysis on:

  • Anal Cancer Therapeutics Market Segments
  • Anal Cancer Therapeutics Market Dynamics
  • Historical Actual Market Size, 2013 – 2015
  • Anal Cancer Therapeutics Market Size & Forecast 2016 to 2022
  • Anal Cancer Therapeutics Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Anal Cancer Therapeutics Drivers and Restraints

Regional analysis includes

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Report Highlights:

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size Recent industry trends
  • Key Competition landscape
  • Strategies of key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

Browse Full PDF: Anal Cancer Therapeutics Market

Global Rheumatoid Arthritis Diagnosis Test Market is expected to be valued at US$ 738.7 Mn by 2022

Rheumatoid arthritis (RA) is an autoimmune disease that causes the body’s immune system to attack joint tissues, which leads to inflammation of joint lining. Such inflammation of joint lining causes pain, stiffness, swelling, warmth, and redness. Rheumatoid arthritis is most prevalent among women. RA can be diagnosed through two methods, namely X–ray imaging and blood tests/serology test.

View Detail Report With TOC: http://www.persistencemarketresearch.com/market-research/rheumatoid-arthritis-market.asp

Global rheumatoid arthritis diagnosis tests market has been estimated to be valued at US$ 485.5 Mn in 2015, and is anticipated to increase to US$ 738.7 Mn by 2022, registering a CAGR of 6.2% during the forecast period. Incidence of RA are increasing among children in Europe and North America. This increased incidence rate calls for adoption of minimally-invasive test methods to diagnose rheumatoid arthritis. Hence, there is high demand for RA test kits with minimally-invasive testing method in Europe and North America.

By test type, the global rheumatoid arthritis diagnosis tests market is segmented into serology test and RA treatment efficiency monitoring tests. Serology test segment is further sub-segmented into erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), antinuclear antibody (ANA), uric acid test, and other tests. RA treatment efficiency monitoring tests segment is further sub-segmented into Salicylate Level Count, Muscle Enzyme Tests (CPK, Aldolase), and Creatinine Test.

By end user, the global rheumatoid arthritis diagnosis tests market is segmented into a hospital, diagnostic laboratories, and ambulatory surgical centers. Diagnostic laboratory segment is further sub-segmented into private laboratories and public laboratories.

By region, the global rheumatoid arthritis diagnosis tests market is segmented into North America, Latin America, Europe, Asia-Pacific and the Middle East & Africa. Europe and Asia Pacific regions have been estimated to account for 61% market share in 2015.

Request Brochure of this Report: http://www.persistencemarketresearch.com/samples/4788

Key players operating in the Rheumatoid Arthritis market include Abbott Diagnostics (Abbott Laboratories), Antibodies Inc., Beckman Coulter, Inc., Euro Diagnostica AB, F. Hoffmann-La Roche Ltd., Qiagen NV, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc.

Browse Full PDF: Rheumatoid Arthritis Diagnosis Test Market

Prophylactic Hepatitis B Virus Vaccines Market : Global Industry Analysis and Forecast 2016 – 2024

Hepatitis B virus (HBV) is disease related to the liver. Hepatitis B virus (HBV) infection results in deaths due to liver cancer and liver failure. The hepatitis B vaccine is available for all age groups to prevent HBV infection. The disease is caused due to transmission of Hepatitis B virus (HBV) through contact with body fluids, blood and semen of an infected person. Hepatitis B disease can cause acute and later may turn to chronic disease if not treated at early stage. In 2015, WHO estimated that 240 Mn people are infected with chronic hepatitis B virus. Every year more than 780,000 deaths occur due to complexity of hepatitis B viral infection. This infection caused by chronic hepatitis B virus develops fulminant hepatitis B (autoimmune disorder), liver cirrhosis, hepatocellular carcinoma (liver cancer), liver failure which can be treated by a liver transplant. The Global Alliance for Vaccines and Immunization (GAVI) provides direction and support to prevent transmission through vaccination. However, there is a significant decrease in incidence of hepatitis B virus infection after introduction of hepatitis B vaccine.

Interested in report: Please follow the below links to meet your requirements; Request for the Report Sample: http://www.persistencemarketresearch.com/samples/10571 (more…)

Rheumatoid Arthritis Diagnosis Test Market has been Estimated to be Valued at US$ 485.5 Mn in 2015

Persistence Market Research (PMR) delivers key insights on the Rheumatoid Arthritis Market in its latest report titled ‘Global Market Study on Rheumatoid Arthritis Diagnosis Tests: Increasing Efficiency of RA Test Kits to Drive Growth of the Market during the Forecast Period, 2015 – 2022’.

Interested in report: Please follow the below links to meet your requirements; 

Request for the Report Brochure: http://www.persistencemarketresearch.com/samples/4788

The rheumatoid arthritis diagnosis tests market is expected to be valued at US$ 738.7 Mn by the end of 2022, expanding at a CAGR of 6.2% during the forecast period (2016–2022). Based on type of tests, the rheumatoid arthritis diagnosis tests market is segmented into serology test and treatment monitoring tests. Increasing incidence of autoimmune diseases, off-label prescription of NSAIDs and other pain management drugs are projected to increase demand for RA diagnosis. In addition, extensive focus on the high specificity and sensitivity of RA kits from kit manufacturers and favorable regulatory guidelines for rapid RA diagnostic kits are expected to fuel market growth. Commercialization of rapid diagnostic test, especially in anti-CCP test would provide key growth opportunities for RA test kits manufacturers.

However, higher costs of these test kits and limited sensitivity when performed as individual test are major restraining factors for this market. Revenue contribution of anti-CCP test segment has been estimated to be the highest, accounting for 31.0% of the total rheumatoid arthritis market share in 2015 and is expected to be one of the most lucrative segments over the forecast period. Limited sensitivity of other tests such as ANA antibody and RF test provide competitive advantage over anti-CCP test. However, availability of these tests at remote location of Asia Pacific region is a major challenge for the market.

Commercialization of cost-effective drugs to treat rheumatoid arthritis is expected promote growth of RA diagnosis tests market, as these medications require continuous monitoring of patients. Moreover, application of biomarker test for diagnosing rheumatoid arthritis could be the future for RA diagnosis, as various companies are focusing on development of biomarker test owing to limited efficacy of test kits currently available in the market.

On the basis of test type, the rheumatoid arthritis diagnosis tests market is segmented into serology test and RA treatment efficiency monitoring tests. Serology test segment is sub-segmented into Erythrocyte Sedimentation Rate (ESR) Tests, Rheumatoid Factor (RF) Tests, Anti-cyclic citrullinated peptide (anti-CCP) Tests, Antinuclear antibody (ANA) tests, uric acid tests and other tests. Anti-cyclic Citrullinated Peptide (anti-CCP) Tests sub-segment exhibits highest growth potential in overall serology test segment, and is projected to exhibit a CAGR of 7.4% during the forecast period; this is mainly attributed to its high sensitivity in early stage diagnosis of rheumatoid arthritis. RA treatment efficiency monitoring test segment is further sub-segmented into salicylate level count test, muscle enzyme tests (CPK, Aldolase) test and creatinine test. Salicylate level count test sub-segment has been estimated to hold highest share of ~46% in terms of revenue in 2015, owing to increase in off-label prescription of pain killer drugs such as Aspirin as RA treatment.

On the basis of geography, the rheumatoid arthritis diagnosis tests market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Europe and Asia Pacific regions have been estimated to collectively account for around 60% revenue share in 2015, owing to higher adoption of RA diagnosis test and increasing prevalence rate of autoimmune diseases. However, high RA prevalent region (North America) tend to become saturated in terms of revenue generation, owing to increasing awareness and healthcare spending for RA treatment and monitoring.

The report begins with an overview of the rheumatoid arthritis diagnosis tests market in terms of value, and a detailed analysis of key trends, drivers and restraints, and opportunities, which are the main factors impelling growth of the rheumatoid arthritis test market. Impact analysis of key growth drivers and restraints based on the weighted average of each of these factors in a model-based approach is included in the report. The report provides in-depth information on potential scope of high-end confirmatory testing kits to provide clients with crystal clear decision-making insights.

Request TOC (table of content), Figures and Tables of the Report: http://www.persistencemarketresearch.com/toc/4788

Key players operating in the rheumatoid arthritis diagnosis tests market include Abbott Diagnostics (Abbott Laboratories), Antibodies Inc., Beckman Coulter, Inc., Euro Diagnostica AB, F. Hoffmann-La Roche Ltd., Qiagen NV, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc. These companies are focusing on commercialization of cost-effective, highly-sensitive and rapid test kits. However, there is stiff competition from local manufacturers owing to low entry barriers and limited awareness about RA test efficiency among physicians.

MicroBiome Therapeutic Market – Segments, Dynamics, Size and Forecast (2015 – 2021)

Scientific investigations has been conducted on the role of microbes and their potential use in preventing and treating diseases. Microbiome is the multifarious assemblage of microorganisms, genes and their metabolites, inhabiting the human and animal mucosal sides, gastric tract and on the skin. It is known that the microbiome interacts with its host and thus assists in ingestion and detoxification, providing immunity, defending against pathogens, and sustaining a good health. Studies have revealed that healthy individuals are often colonized with different microbiomes than those suffering from various disease. It is used for maintaining good health both in humans and animals. (more…)

Global HAIs (Hospital-Acquired Infections) Control Market will reach $82,889.4 million in 2020

New York City, New York, March 10, 2016Malnutrition and poor sanitation are a major cause of hospitalization in the economically weak population worldwide, states a recent market study from Persistence Market Research (PMR). For such reasons, the global hospital-acquired infections (HAIs) control market is poised to grow at a healthy CAGR of 8.5% from 2014 to 2015. (more…)

Global Disposable Plastic Blood Bags Market will reach US$ 4,13,084.8 thousand in 2020

New York City, New York, March 09, 2016: A market research report published by Persistence Market Research, titled “Global Disposable Plastic Blood Bags Market will reach US$4,13,084.8 thousand in 2020”, is a comprehensive analysis of the current state of the global market for disposable plastic bags. The report studies the key driving forces, restraints, trends, and an overview of recent developments in the global market that can collectively shape the market’s future in the years to come. (more…)

Tag Cloud